NeoGenomics, Inc. (NEO) fair value analysis
Nasdaq · Updated 2026-08-24
Valuation status
Awaiting full valuationNEO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $15.84
- Sector
- Healthcare
- 12-month range
- $7.75–$15.84
What our data shows for NEO
- Our model validated 1 trailing price-to-earnings windows for NEO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $7.75–$15.84.
- The 14-day relative strength index sits at a neutral 65.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for NEO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.